Back to all webinars
Highlights from ASH 2021: Practice-changing developments
Christian Buske, Paolo Ghia, Wojciech Jurczak and Véronique Leblond review the most exciting announcements from ASH 2021, covering key developments in a range of lymphomas and leukemias including MCL, DLBCL, and CLL.
Speakers
ASH 2021 highlights: Mantle cell lymphoma
Fast-forward to:
Rituximab maintenance regimens in MCL
62ebba6aea53dd10d5f5d29f
R-HAD plus bortezomib in R/R MCL
62ebc36bea53dd10d5f5d2d4
Covalent BTKis in TN and R/R MCL
62ebda4de8cd6810e2873056
Pirtobrutinib in MCL from the Phase I/II BRUIN study
62ecde5ee8cd6810e28730cd
Bispecific antibodies in MCL
62ece06df6524b10d688f4cf
ASH 2021 highlights: Aggressive lymphomas
Fast-forward to:
First-line DLBCL: Preventing CNS relapse
62ed0406ea53dd10d5f5d50a
The POLARIX study and other polatuzumab-based regimens in DLBCL
62ed08e9ea53dd10d5f5d512
In brief: Other highlights in aggressive lymphomas
62ed0da66c032b10dca54543
ASH 2021 highlights in aggressive lymphomas: Summary
62ed14526c032b10dca5454e
ASH 2021 highlights: CLL/SLL
Fast-forward to:
Zanubrutinib vs. bendamustine plus rituximab: The SEQUOIA study
62ed26e0ea53dd10d5f5d5b9
Acalabrutinib vs. idelalisib plus rituximab or bendamustine plus rituximab: The ASCEND study
62ed2a3c6c032b10dca545b6
Non-covalent BTK inhibitors in CLL
62ed2aebe8cd6810e2873267
First-line treatment with ibrutinib plus venetoclax: The CAPTIVATE study
62ed2c8b6c032b10dca545da
ASH 2021 highlights in CLL: Summary
62ed7c4be8cd6810e2873284
ASH 2021 highlights: Indolent lymphomas
Fast-forward to:
Zanubrutinib in patients intolerant to other BTK inhibitors
62ed801c6c032b10dca5461e
Bispecific antibodies in R/R follicular lymphoma
62ed80faf6524b10d688f6ab
CAR-T in indolent B-cell lymphomas
62ed819a6c032b10dca54631
In brief: Other highlights in indolent lymphomas
62ed8292ea53dd10d5f5d636
ASH 2021 highlights in indolent lymphomas: Summary
62ed84d7ea53dd10d5f5d640
Discussion and audience Q&A
Fast-forward to:
Should we use chimeric antigen receptor T-cell therapy or bispecific antibodies to treat patients with mantle cell lymphoma in the relapsed/refractory setting?
62ed8ad6e8cd6810e28732e4
Will treatment with BTK inhibitors become first-line therapy for patients with MCL in the future?
62ed8b3ef6524b10d688f6d8
Should we now use polatuzumab in combination with immunochemotherapy as first-line treatment for DLBCL? What are our choices for relapsed/refractory DLBCL?
62ed8b766c032b10dca54657
How would you choose between bispecific antibodies and CAR-T therapy for DLBCL? Would you choose a therapy based on a patient’s age or based on the toxicity or efficacy of the therapy?
62efba19f6524b10d688f70b
Autologous stem cell therapy in MCL and DLBCL
62efbb32ea53dd10d5f5d684
Is immunochemotherapy (ICT) an option for patients with treatment-naive CLL or will targeted therapies replace ICT?
62efbb72f6524b10d688f724
What would you recommend as first-line treatment for patients with CLL and TP53 abnormalities?
62efbbc5ea53dd10d5f5d690
What are the indications for adding an anti-CD20 to BTK inhibitors in patients with CLL?
62efbc18f6524b10d688f730
How do patient age and comorbidities influence the choice between venetoclax plus obinutuzumab vs. a BTK inhibitor in patients with CLL?
62efbc736c032b10dca54699
What is the best first-line treatment for patients with MCL and mutant TP53?
62efbcbd6c032b10dca5469d
What is the mechanism for CD30-targeted therapy efficacy in patients with low levels of CD30 expression?
62efbd19e8cd6810e2873340
Do we know if zanubrutinib and acalabrutinib cross the blood–brain barrier?
62efbd67e8cd6810e2873344
For patients with DLBCL, do you think that CAR-T therapy may be preferred in the future compared with immunotherapy used until progression?
62efbda7e8cd6810e2873349
Can you comment on the survival outcomes from the POLARIX study? Are you expecting a difference in overall survival to emerge with longer term follow-up?
62efbdede8cd6810e2873350
Do you think that non-covalent BTK inhibitors will be used as first-line treatment in MCL or CLL, or will they be reserved for the treatment of patients with relapsing disease?
62efc75ce8cd6810e2873357
Highlights from ASH 2021: Meeting summary
No entries